Skip to main content
SpringerLink
Log in

Mechanisms of cellular resistance to cisplatin

  • Review
  • Published:
Medical Oncology and Tumor Pharmacotherapy Aims and scope Submit manuscript

Abstract

Treatment of cancer patients often fails because of the resistance in the tumor to chemotherapeutic drugs. A better understanding of mechanisms which are active in resistant cells might lead to measures to circumvent the resistance. This review deals with the mechanisms of action of cisplatin (CDDP) and the various causes for CDDP resistance in the tumor cells. Also, possibilities to circumvent CDDP resistancein vitro andin vivo are presented.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rosenberg B, Von Camp L, Krigas T: Inhibition of cell division inEscherichia coli by electrolysis products from a platinum electrode.Nature 205, 698 (1965).

    Article  PubMed  CAS  Google Scholar 

  2. Roberts J J, Fraval H N A: Repair of cis-platinum(II) diammine dichloride-induced DNA damage and cell sensitivity, in Prestayko A W, Crooke S T, Carter S K (eds):Cisplatin: Current Status and New Developments, p. 57. New York, Academic Press (1980).

    Google Scholar 

  3. Teicher B A, Cucchi C A, Lee J B, Flatow J L, Rosowsky A, Frei III E: Alkylating agents:in vitro studies of cross resistance patterns in human cell lines.Cancer Res 46, 4379 (1986).

    PubMed  CAS  Google Scholar 

  4. Frei III E, Cucchi C A, Rosowsky A, Tantravani R, Bernai S, Ervin T J, Ruprecht R M, Haseltine W A: Alkylating agent resistance:in vitro studies with human cell lines.Proc natn Acad Sci USA 82, 2158 (1985).

    Article  CAS  Google Scholar 

  5. Eicholtz-Wirth H, Hietel B: The relationship between cisplatin sensitivity and drug uptake into mammalian cellsin vitro.Br J Cancer 54, 239 (1985).

    Google Scholar 

  6. Teicher B A, Holden S A, Kelley M J, Shea T C, Cucchi C A, Rosowsky A, Henner W D, Frei III E: Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II).Cancer Res 47, 388 (1987).

    PubMed  CAS  Google Scholar 

  7. Andrews P A, Murphy M P, Howell S B: Characterization of cisplatin-resistant colo 316 human ovarian carcinoma cells.Proc Am Assoc Cancer Res 27, 289 (1986).

    Google Scholar 

  8. Richon V M, Coday N A, Eastman A: Multiple mechanisms of cis-diamminedichloroplatinum(II) resistance in a murine leukemia L1210 cell line.Proc Am Assoc Cancer Res 27, 291 (1986).

    Google Scholar 

  9. Waud W R, Blount S R: Biochemical studies on resistance to civ-platinum (cis-DDP) in L1210 leukemia.Proc Am Assoc Cancer Res 26, 260 (1985).

    Google Scholar 

  10. Roberts J J, Rawlings C J, Friedlos F: DNA repair characteristics of Walker rat carcinoma cells sensitive and resistant to cis-diamminedichloro platinum(II) (cisplatin) and difunctional alkylating agents, in Harrap K R, Davis W, Calvert A H (ed.):Cancer Chemotherapy and Selective Drug Development, p. 389. Boston, Martinus Nijhoff (1984).

    Google Scholar 

  11. Rosenberg B: Fundamental studies with cisplatin.Cancer 55, 2302 (1985).

    Google Scholar 

  12. Andrews P A, Howell S B: Cisplatin uptake in human ovarian carcinoma cells.Proc Am Assoc Cancer Res 28, 314 (1987).

    Google Scholar 

  13. Byfield J E, Calabro-Jones P M: Carrier-dependent and carrier-independent transport of anti-cancer alkylating agents.Nature 294, 281 (1981).

    Article  PubMed  CAS  Google Scholar 

  14. Shionoya S, Lu Y, Scanlon K J: Properties of amino acid transport systems in K562 cells sensitive and resistant to cis-diamminedichloroplatinum(II).Cancer Res 46, 3445 (1986).

    PubMed  CAS  Google Scholar 

  15. Kano Y, Sakamoto S, Kasahara T, Hida K, Suda K., Ozawa K, Miura Y, Takaku F: Methionine dependency of cell growth in normal and malignant hemopoietic cells.Cancer Res 42, 3090 (1982).

    PubMed  CAS  Google Scholar 

  16. Gross R B, Scanlon K J: Amino acid membrane transport properties of L1210 cells resistant to cisplatin.Chemoterapia V, 37 (1986).

    Google Scholar 

  17. Aggarwal S K, Niroomand-Rad I: Effect of cisplatin on the plasma membrane phosphatase activities in ascites sarcoma-180 cells.J. Histochem Cytochem 31, 307 (1983).

    PubMed  CAS  Google Scholar 

  18. Guarino A M, Miller D S, Arnold S T, Pritchard J B, Davis R D, Urbanek M A, Miller T J, Litterst C L: Platinate toxicity: past, present, and prospects.Cancer Treat Rep 63, 1475 (1979).

    PubMed  CAS  Google Scholar 

  19. Howell S B, Vick J, Andrews P A: Biochemical modulation of cisplatin by dipyridamole.Proc Am Assoc Cancer Res 28, 313 (1987).

    Google Scholar 

  20. Hromas R A, Barlogie B, Meyn R E, Andrews P A, Burns C P: Diverse mechanisms and methods of overcoming cis-platinum resistance in L1210 leukemia cells.Proc Am Assoc Cancer Res 26 261 (1985).

    Google Scholar 

  21. Colombo A, Di Gioia R, Pasini A: Antitumor complexes of platinum with carrier molecules. Cytotoxicity of some platinum amino acid complexes against cisplatin-sensitive and resistant L1210 leukemia cells.Inorg Chim Acta 125, L1 (1986).

    Article  CAS  Google Scholar 

  22. Ikeda H, Nakano G, Nagashima K, Sakamoto K, Harasawa N, Kitamura T, Nakamura T, Nagamachi Y: Verapamil enhancement of antitumor effect ofcis-diamminedichloroplatinum(II) in nude mouse-grown human neuroblastoma.Cancer Res 47, 231 (1987).

    PubMed  CAS  Google Scholar 

  23. Onada J M, Nelson K K, Cox E G, Honn K V: Calcium channel blocker enhancement of cisplatin cytotoxicity: comparison of different chemical classes.Proc Am Assoc Cancer Res 28, 286 (1987).

    Google Scholar 

  24. Ohkuma S, Nishihira T, Toyoda T, Koike N, Izumi U, Kasai M: The antitumor effect of combination therapy with amino acid imbalance and chemotherapyin vitro.J Jap Soc Fd Nutr 20, 89 (1986).

    CAS  Google Scholar 

  25. Lippard S J: New chemistry of an old moleculecis-(Pt(NH3)2Cl2).Science 218, 1075 (1982).

    Article  PubMed  CAS  Google Scholar 

  26. Andrews P A, Kim R W, Murphy M P, Howell S B: Altered cisplatin metabolism in cisplatin-resistant 2008 human ovarian carcinoma cells.Proc Am Assoc Cancer Res 27, 270 (1986).

    Google Scholar 

  27. Roberts J J, Knox R J, Friedlos F, Lydall D A: DNA as the target for the cytotoxic and antitumour action of platinum co-ordination complexes: comparativein vitro andin vivo studies of cisplatin and carboplatin, in McBrien D C H, Slater T F (eds):Biochemical Mechanisms of Platinum Antitumour Drugs, p. 29. Oxford, Washington, DC, IRL Press (1986).

    Google Scholar 

  28. Vassilev P M, Kanazirka M P, Charamella L J, Dimitrov N V, Ti Tien H: Changes in calcium channel activity in membranes from cis-diammine-dichloroplatinum(II)-resistant and -sensitive L1210 cells.Cancer Res 47, 519 (1987).

    PubMed  CAS  Google Scholar 

  29. Litterst C L, Bertolero F, Uozumi J: The role of glutathione and metallothionein in the toxicity and subcellar binding of platinum, in McBrien DCH, Slater T F (eds):Biochemical Mechanisms of Platinum Antitumour Drugs, p. 227. Oxford, Washington, DC, IRL Press (1986).

    Google Scholar 

  30. Behrens B C, Hamilton T C, Masuda H, Grotcinger K R, Whang-Peng J, Lonie K G, Knutsen T, McKay W M, Young R C, Ozols R F: Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.Cancer Res 47, 414 (1987).

    PubMed  CAS  Google Scholar 

  31. Russo A, DeGraft W, Friedman N, Mitchell J B: Selective modulations of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs.Cancer Res 46 2845 (1986).

    PubMed  CAS  Google Scholar 

  32. Hospers G A P, Mulder N H, de Vries E G E: Characterization of a cis-diamminedichloroplatinum (CDDP) resistant human small cell lung carcinoma (hSCLC) cell line.Proc Am Assoc Cancer Res 28, 295 (1987).

    Google Scholar 

  33. Hamilton T C, Winker M A, Lonie K G, Batist G, Behrens B C, Tsuruo T, Grotzinger K R, McKoy W M, Young R C, Ozols R F: Augmentation of adriamycin, melphalan and cisplatin cytotoxicity in drug resistant and sensitive human ovarian cancer cell lines by buthionine sulfoxinine mediated glutathione depletion.Biochem Pharmac 34, 2583 (1985).

    Article  CAS  Google Scholar 

  34. Andrews P A, Velury S, Katra M A, Howell S B: Methionine does not modulate cisplatin cytotoxicity in human ovarian carcinoma cells.Proc Am Assoc Cancer Res 28, 329 (1987).

    Google Scholar 

  35. Karin M, Haslinger A, Holtgreve H, Richards R I, Krauter P, Westphal H M, Beato M: Characterization of DNA sequences through which cadmium and glucocorticoid hormones induce human metallothionein-IIA gene.Nature 308, 513 (1984).

    Article  PubMed  CAS  Google Scholar 

  36. Beach L T, Palmiter R D: Amplification of the metallothionein-I gene in cadium-resistant mouse cells.Proc natn Acad Sci USA 78, 2110 (1981).

    Article  CAS  Google Scholar 

  37. Nagamma A, Satoh M, Imura N: Prevention of lethal and renal toxicity of cis-diamminedichloroplatinum (II) by induction of metallothianein synthesis without compromising its antitumor activity in mice.Cancer Res 47, 983 (1987).

    Google Scholar 

  38. Erdresen L, Sdjerven L, Rugstad H E: Tumours from a strain with a high content of metallothionein show enhanced resistance against cis-dichlorodiammineplatinum.Acta Pharmac Toxic 55, 183 (1984).

    Google Scholar 

  39. Bakka A, Erdressen L, Johnsen A B, Edminson P D, Rugstad D E: Resistance against cis-dichloro-diammineplatinum in cultured cells with a high content of metallothionein.Toxic appl Pharmac 61, 215 (1981).

    Article  CAS  Google Scholar 

  40. Murphy M P, Andrews P A, Howell S B: Metallothionein mediated cisplatin and melphalan in human ovarian carcinoma.Proc Am Assoc Cancer Res 26, 344 (1985).

    Google Scholar 

  41. Peyrot V, Briand C, Crevat A, Bragner D, Chauvet-Monges A M, Sari J L: Action of hydrolyzed cisplatin and some analogs or microtubule protein polymerizationin vitro.Cancer Treat Rep 67, 641 (1983).

    PubMed  CAS  Google Scholar 

  42. Ozols R F, Cowan K: New aspects of clinical drug resistance: the role of gene amplification and the reversal of resistance in drug refractory cancer, in De Vita V T, Hellman S, Rosenberg S A (eds):Important Advances in Oncology, p. 150. Philadelphia, J B Lippincott (1986).

    Google Scholar 

  43. Macquet J P, Butour J L, Johnson NP, Razaka H, Salles B, Vienssens C, Wright M: Is DNA the real target of antitumor platinum compounds?, in Plackes M P, Douple E B, Krakoff I H (eds):Platinum Coordination Complexes in Cancer Chemotherapy, p. 27. Boston, Martinus Nijhoff (1984).

    Google Scholar 

  44. Foka M, Paoletti J: Interaction ofcis-diamminedichloroplatinum(II) to chromatin. Specificity of the drug distribution.Biochem Pharmac 35, 3282 (1986).

    Article  Google Scholar 

  45. Fichtinger-Schepman A M J, van der Veer J L, den Hartog J H J, Lohman P H M, Reedijk J: Adducts of the antitumor drug cisDiamminedichloroplatinum (II) with DNA: formation, identification, and quantitation.Biochemistry 24, 707 (1985).

    Article  PubMed  CAS  Google Scholar 

  46. Eastman A: Interstrand cross-links and sequence specificity in the reaction of cis-dichloro (ethylenediamine) platinum(II) with DNA.Biochemistry 24, 5027 (1985).

    Article  PubMed  CAS  Google Scholar 

  47. Fichtinger-Schepman A M J, Lohman P H M, Reedijk J: Detection and quantification of adducts formed upon interaction of diamminedichloroplatinum(II) with DNA, by anion exchange chromatography after enzymatic degradation.Nucl Acids Res 10, 5345 (1982).

    Article  PubMed  CAS  Google Scholar 

  48. Inagaki K, Kidani Y: Cis-dichlorodiammineplatinum(II) has a binding specificity for adjoining guanine bases.Inorg Chim Acta 106, 187 (1985).

    Article  CAS  Google Scholar 

  49. Plooy A C M, van Dijk M, Lohman P H M: Induction and repair of DNA cross-links in Chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity.Cancer Res 44, 2043 (1984).

    PubMed  CAS  Google Scholar 

  50. Johnson N P, Mazard Am, Escalier J, Macquet J P: Mechanism of the reaction between cis-(PtCl2(NH3)2) and DNAin vitro.J Am Chem Soc 107, 6376 (1985).

    Article  CAS  Google Scholar 

  51. Rahn R O: Chromatographic analysis of the adducts formed in DNA complexed withcis-diamminedichloroplatinum(II).J inorg Biochem 21, 311 (1984).

    Article  PubMed  CAS  Google Scholar 

  52. Johnson N P: Preliminary characterization of the adducts formed between the antitumor compoundcis-Pt(NH3)2Cl2 and DNA.Biochem biophys Res Commun 104, 1394 (1981).

    Article  Google Scholar 

  53. Eastman A, Richon V M: Mechanisms of cellular resistance to platinum coordination complexes, in McBrien D C H, Slater T F (eds):Biochemical Mechanisms of Platinum Antitumour Drugs, p. 91. Oxford, Washington, DC, IRL Press (1986).

    Google Scholar 

  54. Plooy A C M, Fichtinger-Schepman A M J, Schutte H M, van Dijk M, Lohman P H M: The quantitative detection of various Pt-DNA-adducts in Chinese hamster ovary cells treated with cisplatin: application of immunochemical techniques.Carcinogenesis 6, 561 (1985).

    Article  PubMed  CAS  Google Scholar 

  55. Pera M F, Rawlings C J, Shackleton J, Roberts J J: Qualitative aspects of the formation and loss of DNA interstrand crosslinks in Chinese hamster cells following treatment with cis-diamminedichloroplatinum(II) (cisplatin). II: Comparison of results from alkaline elution, DNA renaturation DNA sedimentation studies.Biochim biophys Acta 655, 152 (1981).

    PubMed  CAS  Google Scholar 

  56. Zwelling L A, Anderson T, Kohn K W: DNA-protein and DNA interstrand crosslinking bycis- and trans-platinum(II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity.Cancer Res 39, 365 (1979).

    PubMed  CAS  Google Scholar 

  57. Butour J L, Johnson N P: Chemical reactivity of monofunctional platinum-DNA adducts.Biochemistry 25, 4534 (1986).

    Article  PubMed  CAS  Google Scholar 

  58. Filipshi J, Kohn K W, Bonner W M: Differential crosslinking of histones and non-histones in nuclei by cis-Pt (II).FEBS Letters 152, 105 (1983).

    Article  Google Scholar 

  59. Olinski R, Wedrychowski A, Schmidt W N, Briggs R C, Hnilica L S:In vivo DNA-protein cross-linkings bycis- and trans-diamminedichloroplatinum(II).Cancer Res 47, 201 (1987).

    PubMed  CAS  Google Scholar 

  60. Zwelling L A, Anderson T, Kohn K W: DNA-protein and DNA interstrand crosslinking bycis- and trans-platinum(II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity.Cancer Res 39, 365 (1979).

    PubMed  CAS  Google Scholar 

  61. Zwelling L A, Michaels S, Schwartz H, Dobson P P, Kohn K W: DNA crosslinking as an indicator of sensitivity and resistance of mouse L1210 leukemia tocis-diamminedichloroplatinum(II) and l-phenylalanine mustard.Cancer Res 41, 640 (1981).

    PubMed  CAS  Google Scholar 

  62. Strandberg M C, Bresnick E, Eastman A: DNA crosslinking induced in 1,2-diamino-cyclo-hexanedichloroplatinum(II) in murine leukemia L1210 cells and comparison with other platinum analogues.Biochim biophys Acta 698, 128 (1982).

    PubMed  CAS  Google Scholar 

  63. Micetich K, Zwelling L A, Kohn K W: Quenching of DNA: platinum(II) monoadducts as a possible mechanism of resistance to cis-diammine dichloroplatinum(II) in L1210 cells.Cancer Res 43, 3609 (1983).

    PubMed  CAS  Google Scholar 

  64. Strandberg M C, Bresnick E, Eastman A: The significance of DNA crosslinking tocis-diamminedichloroplatinum(II)-induced cytotoxicity in sensitive and resistant lines of murine leukemia L1210 cells.Chem biol Interact 39, 169 (1982).

    Article  PubMed  CAS  Google Scholar 

  65. Eastman A: Comparison of the adducts formed in DNA bycis- and trans-diamminedichloroplatinum (II).Proc Am Assoc Cancer Res 27, 291 (1986).

    Google Scholar 

  66. Ehrlich M, Wang R Y M: 5-methylcytosine in eukaryotic DNA.Science 212, 1350 (1981).

    Article  PubMed  CAS  Google Scholar 

  67. Reed E, Litterst C L, Yuspa S H, Poirier M C: Sex differences in cisplatin-DNA adduct formation in an animal model.Proc Am Assoc Cancer Res 26, 260 (1985).

    Google Scholar 

  68. Reed E, Litterst C, Yuspa S H, Poirier M C: Cisplatin-DNA adducts persistence in renal and gonadal tissues of male and female rats.Proc Am Assoc Cancer Res 28, 450 (1987).

    Google Scholar 

  69. Inskeep P B, Koga N, Cmarik J L, Guengerich F P: Covalent binding of 1,2-dihaloalkanes to DNA and stability of the major DNA adducts, S-[2-(N 7-guanyl)ethyl]glutathione.Cancer Res 46, 2839 (1986).

    PubMed  CAS  Google Scholar 

  70. Hung D T, Marton L J, Deen D F, Shafer R H: Depletion of intracellular polyamines may alter DNA conformation in gL rat brain tumor cells.Science 221, 368 (1983).

    Article  PubMed  CAS  Google Scholar 

  71. Purchase I F M: Inter-species comparisons of carcinogenicity.Br J Cancer 41, 454 (1980).

    PubMed  CAS  Google Scholar 

  72. Eastman A: Mechanisms of resistance to platinum drugs, in Nicolini M, Bandoli G (eds):Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. In press.

  73. Hamilton T C, Masuda H, Young R C, Ozols R F: Modulation of cisplatin (CP) cytotoxicity by inhibition of DNA repair in a cisplatin resistant human ovarian cancer cell line 2780 CP.Proc Am Assoc Cancer Res 28, 291 (1987).

    Google Scholar 

  74. Allen E D, Natale R B: Effect of α-difluoro-methylornithine alone and in combination with doxorubicin hydrochloride, cis-diammine-dichloroplatinum(II), and vinblastine sulfate on the growth of P3J cellsin vitro.Cancer Res 46, 3550 (1986).

    PubMed  CAS  Google Scholar 

  75. Ota D M, Grossie V B, Ajani J A, Stephans L C, Nishioka K: Red blood cell polyamine levels and host toxicity during continuous alpha-difluoromethylornithine infusion.Int J Cancer 38, 245 (1986).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Department of Internal Medicine, University Hospital, Oostersingel 59, 9713, EZ Groningen, The Netherlands

    G. A. P. Hospers, N. H. Mulder & E. G. E. De Vries

Authors
  1. G. A. P. Hospers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. H. Mulder
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. G. E. De Vries
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hospers, G.A.P., Mulder, N.H. & De Vries, E.G.E. Mechanisms of cellular resistance to cisplatin. Med. Oncol. & Tumor Pharmacother. 5, 145–151 (1988). https://doi.org/10.1007/BF02986437

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02986437

Key words

Search

Navigation